Journal of Renal Nutrition
Volume 19, Issue 4 , Pages 321-333 , July 2009

Effect of Aggressive Osteodystrophy Management on Clinical Outcomes in Stage 5 Chronic Kidney Disease

  • Laura Byham-Gray, PhD, RD

      Affiliations

    • Department of Nutritional Sciences, University of Medicine and Dentistry of New Jersey, School of Health-Related Professions, Stratford, NJ
    • Corresponding Author InformationAddress reprint requests to Laura Byham-Gray, PhD, RD, Department of Nutritional Sciences, University of Medicine and Dentistry of New Jersey, School of Health-Related Professions, University Educational Center, Room 2111, 40 East Laurel Road, Stratford, NJ 08084.
    • ,
  • Tammy Drasher, RD, LDN

      Affiliations

    • Dialysis Clinic, Inc., North Billerica, MA
    • ,
  • Karen Deckman, MA, RD, LDN

      Affiliations

    • Dialysis Corporation of America (formerly), Vineland, NJ
    • ,
  • Diane Graham, MS, RD, LDN

      Affiliations

    • Hershey Medical Center-Dialysis Unit, Hershey, PA
    • ,
  • Carol Liftman, MS, RD, LDN

      Affiliations

    • Franklin Dialysis Center/DaVita, Philadelphia, PA
    • ,
  • Linda Roberto, MA, RD, LDN

      Affiliations

    • Fresenius Medical Care-Mount Airy, Philadelphia, PA
    • ,
  • Phyllis Peiffer, MBA, RD, LDN

      Affiliations

    • Wellspan Dialysis, York, PA
    • ,
  • Robert Denmark, PhD

      Affiliations

    • University of Medicine and Dentistry of New Jersey, School of Health-Related Professions, Newark, NJ

References 

  1. National Kidney Foundation . KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003;42:S1–S202
  2. Hruska K, Saab G, Matthew S, et al. Renal osteodystrophy, phospate homeostasis, and vascular calcification. Semin Dial. 2007;20:309–315
  3. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945–1953
  4. Rix M, Andreassen H, Eskildsen P, et al. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int. 1999;56:1084–1093
  5. Malluche H, Faugere MC. Effects of 1,25(OH)2D3 administration on bone in patients with renal failure. Kidney Int. 1990;29:S48–S53
  6. Levin A, Bakris G, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31–38
  7. Weisinger J, Carlini RG, Rojas E, et al. Bone disease after transplantation. Clin J Am Soc Nephrol. 2006;1:1300–1313
  8. Goodman W. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Semin Dial. 2004;17:209–216
  9. de Francisco A. Secondary hyperparathyroidism: Review of the disease and its treatment. Clin Ther. 2004;26:1976–1993
  10. Block G, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for change in management. Am J Kidney Dis. 2000;35:1226–1237
  11. Giachelli C. Vascular calcification mechanisms. J Am Soc Nephrol. 2004;15:2959–2964
  12. Block H-S, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31:607–617
  13. Kalantar-Zadeh K, Kuwae N, Regiodor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70:771–780
  14. Pisoni R, Greenwood RN. Selected lessons learned from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Contrib Nephrol. 2005;149:58–68
  15. Block G, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516–1525
  16. Manley H, Carvin CG, Drayer DK, et al. Medication prescribing patterns in ambulatory haemodialysis patients: Comparison of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transplant. 2004;19:1842–1848
  17. Lindberg J, Cullerton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005;16:800–807
  18. Block G, Zeig S, Sugihara J, et al. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant. 2008;23:2311–2318
  19. Young E, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:34–38
  20. McCann L. KDOQI Practice Guidelines for Bone Metabolism and Disease in CKD: Another opportunity for renal dietitians to take a leadership role in improving outcomes for patients with CKD. J Ren Nutr. 2005;15:265–274
  21. Martin C, Reams SM. The renal dietitian's role in managing hyperphosphatemia and secondary hyperparathyroidism in dialysis patients: A national survey. J Ren Nutr. 2003;13:133–136
  22. Goodman W. The evolution of assays for parathyroid hormone. Semin Dialysis. 2005;18:296–301
  23. Souberbielle J, Friedlander G, Cormier C. Practical considerations in PTH testing. Clin Chim Acta. 2006;366:81–89
  24. Block G, Klasseb PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis patients. J Am Soc Nephrol. 2004;15:2208–2218
  25. Winkelmayer W, Tonelli M. Phosphate binder choice in dialysis patients: A call for evidence-based rather than marketing-based clinical practice. Am J Kidney Dis. 2008;51:362–365
  26. Block G, Zerig S, Sugihara J, Chertow GM, Chi EM, Turner SA, et al. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe hyperparathyroidism. Nephrol Dial Transplant. 2008;23:2311–2318
  27. Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006;70:1858–1865
  28. Heaney R, Barger-Lux MJ, Dowell MS, et al. Calcium absorptive effects of vitamin D and its major metabolites. J Clin Endocrinol Metab. 1997;82:4111–4116
  29. Gallieni M, Brancaccio D, Padovese P, et al. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int. 1992;42:1191–1198
  30. Bleyer A, Burke SK, Dillon M, et al. A comparison of calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis. 1999;694–701
  31. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52:519–530
  32. Manns B, Owen WF, Winkelmayer WC, et al. Surrogate markers in clinical studies: Problems solved or created?. Am J Kidney Dis. 2006;48:159–166
  33. Drueke T. Is parathyroid hormone measurement useful for the diagnosis of renal bone disease?. Kidney Int. 2008;73:674–676
  34. Barreto F, Barreto DV, Moyses RMA, et al. KDOQI recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int. 2008;73:771–777
  35. Block G, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71:438–441
  36. Block G, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815–1824
  37. Chertow G, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–252
  38. St. Peter W, Liu J, Weinhandl E, et al. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: A secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis. 2008;51:445–454
  39. Floege J. Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: Should we CARE-2 avoid them?. Nephrol Dial Transplant. 2008;23:3050–3052

 This work was supported by a Council on Renal Nutrition Research Grant of the National Kidney Foundation.

PII: S1051-2276(09)00040-5

doi: 10.1053/j.jrn.2009.01.018

Journal of Renal Nutrition
Volume 19, Issue 4 , Pages 321-333 , July 2009

Article Tools

* Image Usage & Resolution